| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2018-08-28 | SGS (Switzerland) | construction of new premises | Technology - Services | Construction of new premises | ||
| 2018-08-28 | Allogene Therapeutics (USA - CA) | senior vice president | nomination | Cancer - Oncology | Nomination | |
| 2018-08-23 | Bluebird bio (USA - MA) Gritstone Oncology (USA - CA) | tumor-specific targets and natural T-cell receptors (TCRs) | research - development - commercialisation | Cancer - Oncology | Research agreement | |
| 2018-08-16 | BioNTech (Germany) Pfizer (USA - NY) | mRNA-based flu vaccines | influenza (flu) | research - development - R&D | Infectious diseases | Development agreement |
| 2018-08-14 | Actavalon (USA - CA) | member of the board of directors | nomination | Cancer - Oncology | Nomination | |
| 2018-08-14 | Allogene Therapeutics (USA - CA) | chief development officer | nomination | Cancer - Oncology | Nomination | |
| 2018-08-08 | Sarepta Therapeutics (USA - MA) Lacerta Therapeutics (USA - Fl) | AAV-based CNS-targeted gene therapies | CNS diseases | licensing | CNS diseases | Licensing agreement |
| 2018-08-07 | Infinity Pharmaceuticals (USA - MA) | nomination | Cancer - Oncology | Nomination | ||
| 2018-08-07 | apceth (Germany) | validation of a production plant | Technology - Services | Production agreement | ||
| 2018-08-06 | Allergan (Ireland) Editas Medicine (USA - MA) | up to five of Editas Medicine's genome-editing ocular programs, including EDIT-101 for the treatment of LCA10 | Leber congenital amaurosis type 10 (LCA10) | development - licensing | Rare diseases - Genetic diseases - Ophtalmological diseases | Exercise of an option agreement |
| 2018-08-06 | Boehringer Ingelheim (Germany) Oxford Biomedica (UK) UK Cystic Fibrosis Gene Therapy Consortium (UK) Imperial Innovations (UK) | replication-deficient lentiviral vector in an inhaled formulation, to introduce a healthy copy of the CFTR gene into the cells of the lung | cystic fibrosis | collaboration | Rare diseases - Genetic diseases - Respiratory diseases | Collaboration agreement |
| 2018-08-06 | Bluebird bio (USA - MA) Regeneron Pharmaceuticals (USA - NY) | immune cell therapies | research - development - R&D - commercialisation | Cancer - Oncology | Collaboration agreement | |
| 2018-08-03 | HTG Molecular Diagnostics (USA - AZ) Oncologie (USA - MA) | biomarkers associated with Oncologie’s Immuno-oncology pipeline | development | Development agreement | ||
| 2018-08-02 | Atlantic Healthcare (UK) | US president and chief executive officer | nomination | Inflammatory diseases - Gastrointestinal diseases | Nomination | |
| 2018-08-02 | Orchard Therapeutics (UK) | member of the board of directors | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2018-08-02 | Akcea Therapeutics (USA - CA), a subsidiary of Ionis Pharmaceuticals (USA - CA) PTC Therapeutics (USA - NJ) | Tegsedi™ (inotersen) and Waylivra™ (volanesorsen) | hereditary transthyretin amyloidosis (hATTR), familial chylomicronemia syndrome (FCS) | commercialisation | Rare diseases - Genetic diseases | Commercialisation agreement |
| 2018-08-01 | BioNTech (Germany) SiO2 Medical Products (“SMP”) (USA - Ala) | packaging and application devices for mRNA therapeutics | collaboration | Technology - Services | Collaboration agreement | |
| 2018-08-01 | Celyad (Belgium) | member of the board of directors | nomination | Cancer - Oncology | Nomination | |
| 2018-07-30 | Retrotope (USA - CA) | chief medical officer | Rare diseases | nomination | Nomination | |
| 2018-07-25 | GSK (UK) 23andme (USA - CA) | collaboration - research - development | Collaboration agreement |
